Clinical trials · Charlotte, NC
Cancer clinical trials in Charlotte
We’re tracking 185 recruiting cancer studies with a site in or near Charlotte — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Charlotte
- NCT07173751RecruitingPhase 3
Pumitamig for advanced triple-negative breast cancer
This study tests a new drug called pumitamig for people with a type of breast cancer that is triple-negative or has very low hormone receptors and has come back or spread. It aims to see if pumitamig works better than standard treatment and how safe it is for people who cannot get PD(L)-1 immunotherapy with chemo.
Charlotte, North CarolinaAges 18 years+ - NCT05145400RecruitingPhase 2
Drug treatment for frail or older newly diagnosed multiple myeloma
This Phase 2 study tests whether “isa-Rd” can safely and effectively treat people who have newly diagnosed multiple myeloma and are frail or much older. It may help those who are at higher risk of side effects from stronger, full-intensity chemotherapy.
Charlotte, North CarolinaAges 18 years+ - NCT05174169RecruitingPhase 2/Phase 3
Adjuvant colon chemotherapy guided by tumor DNA results
This trial tests whether treatment for colon cancer after surgery can be guided by a blood test that looks for leftover cancer signals (ctDNA). It may help some people choose stronger or different chemo based on whether ctDNA is found after surgery.
Charlotte, North CarolinaAges 18 years+ - NCT06888921RecruitingPhase 1/Phase 2
COM701 for platinum-sensitive ovarian cancer
This study tests a new drug, COM701, for people with ovarian cancer that came back after treatment but still responds to platinum-based chemotherapy. It aims to see if COM701 is safe and effective for patients who have already tried several treatments.
Charlotte, North CarolinaAges 18 years+ - NCT06077760RecruitingPhase 3
Personalized cancer vaccine plus Keytruda for lung cancer after surgery
This study tests a new personalized cancer vaccine (V940) plus Keytruda versus a placebo plus Keytruda for people with non-small cell lung cancer that was removed by surgery. The goal is to see if the vaccine helps prevent the cancer from coming back.
Charlotte, North CarolinaAges 18 years+ - NCT05886049RecruitingPhase 1
Testing a menin drug with standard chemo for newly diagnosed AML
This early-phase study tests a menin inhibitor drug (SNDX-5613) combined with standard induction chemotherapy (daunorubicin plus cytarabine) in newly diagnosed AML with specific gene changes (NPM1 or FLT3 status, or MLL/KMT2A or NUP98). It may help patients whose AML has these genetic features respond better to intensive treatment.
Charlotte, North CarolinaAges 18–75 - NCT07085767RecruitingPhase 3
Palazestrant and ribociclib for first-line advanced breast cancer
This trial tests a new drug (palazestrant) combined with ribociclib for people with a common type of advanced breast cancer that is estrogen receptor-positive and HER2-negative. You may qualify if you haven't had treatment for advanced disease and your cancer has either just been found or came back long after completing hormone therapy.
Charlotte, North CarolinaAges 18 years+ - NCT03678025RecruitingPhase 3
Standard treatment for metastatic prostate cancer, with or without local treatment
This Phase 3 trial studies whether using the usual medicines for metastatic prostate cancer, plus a definitive local treatment to the prostate, improves outcomes. It may help determine if treating the prostate directly can benefit people whose cancer has not worsened after initial hormone-based treatment.
Charlotte, North CarolinaAges 18 years+ - NCT05125016RecruitingPhase 1/Phase 2
Study drug for advanced prostate cancer after standard treatments
This early-phase study tests whether REGN4336 is safe and how well it works, by itself or with REGN5678, in adults with advanced prostate cancer. It may help people whose cancer has continued to worsen despite standard prostate cancer medicines.
Charlotte, North CarolinaAges 18 years+ - NCT06592924RecruitingPhase 3
Adding chemo to hormone therapy for prostate cancer with slow PSA drop
This trial tests if adding docetaxel chemotherapy helps men whose PSA hasn't dropped enough after at least 6 months of standard hormone therapy (ADT) plus an ARPI pill (like abiraterone or enzalutamide) for metastatic prostate cancer that still responds to hormones.
Charlotte, North CarolinaAges 18 years+ - NCT07194044RecruitingPhase 1
Testing a treatment schedule for metastatic Ewing sarcoma
This trial tests a new schedule of standard chemotherapy drugs to see if it improves outcomes for people with metastatic Ewing sarcoma or CIC-rearranged sarcoma. It is for patients who have not had prior cancer treatment, except possibly one initial cycle of VDC.
Charlotte, North CarolinaAges 1 year+ - NCT07060807RecruitingPhase 3
Study of Patritumab Deruxtecan for Advanced HR+/HER2- Breast Cancer
This trial tests a new drug called patritumab deruxtecan (a targeted therapy) for people with a common type of advanced breast cancer (HR+/HER2-). It's for those whose cancer has grown despite treatment with a CDK4/6 inhibitor plus hormone therapy.
Charlotte, North CarolinaAges 18 years+ - NCT06989112RecruitingPhase 3
First-line treatment for advanced or recurrent endometrial cancer
This trial tests a new combination of drugs for endometrial cancer that has spread or come back. It aims to see if these drugs can shrink tumors and help people live longer. It is for tumors that have a certain protein (HER2) and are mismatch repair proficient (meaning they have a normal DNA repair system).
Charlotte, North CarolinaAges 18 years+ - NCT07723248RecruitingPhase 3
Oral Rinzimetostat for Advanced Prostate Cancer After Abiraterone
This study tests an experimental pill called rinzimetostat (ORIC-944) for men with advanced prostate cancer that has spread and stopped responding to abiraterone. It may offer a new option if you have not had many other treatments yet.
Charlotte, North CarolinaAges 18 years+ - NCT06623422RecruitingPhase 3
Vaccine plus Keytruda for lung cancer after surgery
This trial tests combining a cancer vaccine (V940) with the immunotherapy drug pembrolizumab (Keytruda) for people with non-small cell lung cancer that was treated with chemo and Keytruda before surgery but wasn't completely removed. The goal is to see if adding the vaccine helps prevent the cancer from coming back.
Charlotte, North CarolinaAges 18 years+ - NCT06072781RecruitingPhase 3
Study of Avutometinib + Defactinib for recurrent low-grade ovarian cancer
This trial tests a combination of two oral targeted drugs for people with recurrent low-grade serous ovarian cancer. It aims to see if this therapy works better than standard hormone therapy or chemotherapy options.
Charlotte, North CarolinaAges 18 years+ - NCT05735080RecruitingPhase 1/Phase 2
INX-315 for advanced cancers with a specific gene change
This trial studies an experimental medicine (INX-315) given in an “open-label” way to people with advanced cancer that has not responded to prior treatment. It mainly looks at safety and side effects first, and also checks how well it works in cancers with a specific gene amplification.
Charlotte, North CarolinaAges 18 years+ - NCT06064097RecruitingPhase 2
Nivolumab plus chemo for young people with nasopharyngeal cancer
This trial tests combining the immunotherapy drug nivolumab with standard chemotherapy to treat newly diagnosed nasopharyngeal cancer in children and young adults. The goal is to see if adding this immune-boosting medicine can help shrink tumors and prevent the cancer from coming back.
Charlotte, North CarolinaAges Up to 21 years - NCT06667076RecruitingPhase 2
Amivantamab combinations for advanced EGFR-mutant lung cancer
This trial tests two treatment combinations for people with a specific type of advanced lung cancer that has an EGFR mutation. One group gets amivantamab plus lazertinib, and the other gets amivantamab plus chemotherapy. The goal is to see which combo works better.
Charlotte, North CarolinaAges 18 years+ - NCT06393374RecruitingPhase 3
Study of a new drug combination for residual TNBC after initial treatment
This trial tests a new combination of two drugs (sacituzumab tirumotecan and pembrolizumab) compared to standard chemotherapy for people with triple-negative breast cancer that did not fully respond to initial treatment. It aims to see if this combination helps prevent cancer from coming back.
Charlotte, North CarolinaAges 18 years+ - NCT05099003RecruitingPhase 1/Phase 2
Selinexor plus radiation for newly diagnosed brain tumors
This trial studies whether adding selinexor to standard radiation can improve outcomes for children and young teens with certain newly diagnosed high-grade brain tumors (including DIPG). It’s designed for specific tumor types and genetic markers, and people must be able to start treatment soon after diagnosis.
Charlotte, North CarolinaAges 1–21 - NCT06672146RecruitingPhase 2
New treatments for AML with an IDH2 mutation
This trial tests new treatments for people with newly diagnosed acute myeloid leukemia (AML) that has a change in the IDH2 gene. It aims to find a better option for those who cannot have standard high-dose chemotherapy.
Charlotte, North CarolinaAges 18 years+ - NCT05879926RecruitingPhase 3
Testing chemo after hormone therapy in premenopausal early breast cancer
This Phase 3 trial checks whether adding chemotherapy after standard hormone-blocking treatment works better for some premenopausal women with early-stage, ER-positive, HER2-negative breast cancer. It targets patients with limited lymph node spread and a lower-to-intermediate tumor “recurrence” risk score.
Charlotte, North CarolinaAges 18–60 - NCT05894239RecruitingPhase 3
Tested targeted drug for HER2-positive breast cancer with PIK3CA changes
This Phase 3 study tests inavolisib plus Phesgo versus placebo plus Phesgo in people whose breast cancer has both HER2-positive and PIK3CA-mutated tumor markers. The goal is to see if adding inavolisib improves how well the treatment controls the cancer and how safe it is.
Charlotte, North CarolinaAges 18 years+
Hear when a new Cancer trial opens near Charlotte, NC
We’ll email you when one opens near Charlotte, NC — at most once a week, no account needed, unsubscribe anytime.
Cancer trials in other cities
Where these studies are running near Charlotte
Institutions with a site for the recruiting cancer studies listed above.
- Levine Cancer Institute · 10 studies
- Carolinas Medical Center/Levine Cancer Institute · 7 studies
- Novant Health Presbyterian Medical Center · 5 studies
- Atrium Health Cabarrus · 4 studies
- Atrium Health Union · 4 studies
- Atrium Health University City · 4 studies
- Atrium Health · 3 studies
- Atrium Health Pineville · 3 studies
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting cancer studies in North Carolina.
Common questions
- Are there cancer clinical trials near Charlotte?
- Yes. We're currently tracking 185 recruiting cancer studies with a site near Charlotte, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study near Charlotte?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Charlotte to take part?
- Not necessarily. These studies have a site near Charlotte, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open near Charlotte regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.